Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $43.00.

LYEL has been the subject of a number of recent research reports. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th.

Lyell Immunopharma Price Performance

LYEL opened at $12.63 on Wednesday. The company has a market capitalization of $294.66 million, a price-to-earnings ratio of -0.92 and a beta of -0.09. The firm’s fifty day moving average price is $17.84 and its two-hundred day moving average price is $22.75. Lyell Immunopharma has a 1 year low of $8.46 and a 1 year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. As a group, equities analysts anticipate that Lyell Immunopharma will post -7.87 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its position in shares of Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after purchasing an additional 154,327 shares during the last quarter. Acadian Asset Management LLC lifted its position in Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after purchasing an additional 443,614 shares during the last quarter. Walleye Capital LLC purchased a new position in Lyell Immunopharma in the 2nd quarter worth approximately $258,000. Marshall Wace LLP purchased a new position in Lyell Immunopharma in the 2nd quarter worth approximately $94,000. Finally, Orbimed Advisors LLC bought a new position in shares of Lyell Immunopharma in the 2nd quarter worth $457,000. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.